Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: per strandberg who wrote (3850)	2/19/1998 9:54:00 AM
From: biodoc	of 6136

It is good. Most young biotech companies provide part (in some case most) of the compensation as incentive stock options. As the companies increase in size, the need arises occasionally to increase the shares available for this purpose. While there is some dilution from this, the alternative is to pay higher salaries and bonuses. My guess is the short term effect on stock price would be a wash (does anyone know if this is true?) I work in a biotech firm (not AGPH and I assure you the salary doesn't motivate the 12 hour days, 6 day a week life style, but, along with the scientific interest and ability to work on important drugs, the potential large reward from the options focuses the mind on success.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next